Skip to main content
. Author manuscript; available in PMC: 2012 Sep 25.
Published in final edited form as: Oncogene. 2007 May 7;26(49):6989–6996. doi: 10.1038/sj.onc.1210500

Figure 1. Stearic acid-modified Fus1 peptide inhibits constitutively activated commercial Abl tyrosine kinase.

Figure 1

(a) Stearic acid-modified Fus1 peptide inhibits GST–Crk phosphorylation by a bacterially purified, constitutively active, Abl kinase (IC50 35uM). (b) Without the stearic acid modification, the Fus1 peptide does not inhibit GST–Crk phosphorylation by the bacterially purified, constitutively active, Abl kinase. (c) A stearic acid-modified Bcr peptide does not inhibit GST–Crk phosphorylation by the bacterially purified, constitutively active, Abl kinase. (d) Stearate Fus1 peptide inhibits phosphorylation of a known Abl kinase peptide target, EAIYAAPFAKKK, by full-length human Abl.